Menu
Recruiting NCT02023060

Functional and Quality of Life Improvement Following Transcatheter Heart Valve Implantation

Observational Trans Catheter Aortic Valve Aortic Stenosis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Trans Catheter Aortic Valve, Aortic Stenosis. Basic parameters: 18 years — 110 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Israel
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The objective is to observe trends in patient characteristics and outcomes after aortic or mitral transcatheter heart valve replacement over time.

Detailed description

To observe trends in patient characteristics and outcomes after aortic or mitral transcatheter heart valve replacement over time.

Primary outcome measures

  • Clinical outcome of patients undergoing transcatheter valve replacement [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

  • Subject selected for transcatheter heart valve replacement
  • Signed informed consent to participate in the study

Exclusion criteria

  • Inability to sign written informed consent.
  • Pregnancy or breast feeding (women of childbearing potential will have a serum or urine pregnancy test).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Israel · 5 centers
  • Hadassah Medical Center — Jerusalem
  • Shaarei Zedek amedical Center — Jerusalem
  • Rabin Medical Center — Petah Tikva
  • Sheba Medical Center — Ramat Gan
  • Tel Aviv Medical Center — Tel Aviv

Publications

  • Zusman O, Barbash MI, Guetta V, Finkelstein A, Assali A, Segev A, Orvin K, Barsheshet A, Younis A, Witberg G, Kornowski R, Danenberg H, Landes U. Predicting the risk of late futile outcome after transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2020 Dec;96(7):E695-E702. doi: 10.1002/ccd.28761. Epub 2020 Feb 5. PMID 32022390
  • Brodov Y, Konen E, Di Segni M, Samoocha D, Chernomordik F, Barbash I, Regev E, Raanani E, Guetta V, Segev A, Fefer P, Glikson M, Goitein O. Mitral Annulus Calcium Score. Circ Cardiovasc Imaging. 2019 Dec;12(1):e007508. doi: 10.1161/CIRCIMAGING.117.007508. PMID 30636515

Identifiers

NCT: NCT02023060 · SHEBA-13-0685-IB-CTIL

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗